The Arroven Study (Ma25101): Post-Authorisation Observational Safety Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma
Authors
Linton, Kim MAyto, R
d'Amore, F
Moestl, M
Chau, I
Paneesha, S
Kinley, J
Huebner, D
Porter, J
Exter, B
Wang, B
Tymoszczuk, J
Arumainathan, A
Affiliation
University of Manchester and The Christie NHS Foundation Trust, ManchesterIssue Date
2015